Sunday 4 October 2026
Afternoon EditionRSS
ZOTPAPER

News without the noise

ZOTPAPER
Business

European drugmakers warn leaders they are 'losing ground' to US and China

Chairs of nine major pharma firms urge action to safeguard the continent's drug development and investment

By LineZotpaper
Published
Read Time1 min
Sources2 outlets
Some of Europe's biggest pharmaceutical companies have written to national leaders, including Andy Burnham and counterparts across the continent, warning that Europe is 'losing ground' to US and Chinese rivals in developing new drugs and attracting investment, and calling for action to safeguard their futures.

The chairs of nine major European drugmakers — including Britain's AstraZeneca, GSK and Denmark's Novo Nordisk — sent a letter on Tuesday to Andy Burnham and the national leaders of other European countries, urging intervention to "safeguard our companies' future."

The companies said the continent is falling behind its competitors in the US and China both in drug development and in drawing investment. The letter does not specify which policies they want, but the tone suggests a broad call for European governments to strengthen the region's pharmaceutical competitiveness.

The development comes as Europe faces increasing pressure to retain its position in an industry long dominated by American and, more recently, Chinese players. While the letter names no specific figures, it frames the issue as a matter of urgency for the companies' long-term survival.

§

Analysis

Why This Matters

  • Europe's pharmaceutical sector is a major economic and scientific pillar; losing ground could affect innovation, jobs, and access to new medicines.
  • The letter signals growing anxiety among industry leaders about the continent's ability to compete in a high-stakes global market.
  • How national leaders respond could shape future investment, research incentives, and drug pricing policies across Europe.

Background

Europe has traditionally been a global hub for pharmaceutical research and manufacturing. However, in recent years, the US and China have pulled ahead in areas like biotech and novel therapies, often driven by larger research budgets and more supportive policy environments. This letter appears to be a coordinated push by major firms to put the issue on the political agenda.

Key Perspectives

Pharmaceutical companies: They argue that without intervention, European firms risk falling behind in drug innovation and losing investment to more competitive markets like the US and China. US and Chinese rivals: Their ongoing success — whether through innovation, scale, or policy support — creates pressure on European firms to adapt or decline. Critics/Skeptics: Some may question whether the letter is a bid for subsidies or looser regulation, rather than a genuine concern over competitiveness. There is also a risk that nationalist responses could fragment a single European approach.

What to Watch

  • Any formal response from European leaders or the European Commission to the companies' request.
  • Policy announcements related to pharmaceutical innovation, research funding, or tax incentives in the coming months.
  • Whether other European drugmakers publicly align with or distance themselves from this letter.

Sources

Zotpaper

Written by software from the reporting listed above, scored by an automated standards desk, and published without a person reading it first. If something here is wrong, tell the editor and it will be put right.

How we workReport an errorSubscribe